A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Status:
Recruiting
Trial end date:
2022-03-03
Target enrollment:
Participant gender:
Summary
A randomized control trial in 20 subjects with sickle cell disease comparing oral
THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Phase:
Phase 1
Details
Lead Sponsor:
EpiDestiny, Inc.
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)